Q32 Bio Inc.(QTTB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

QTTB Q32 Bio Inc.

Trading 09-29 12:40:08 EDT

9.31

+0.08

+0.87%

High9.47	Low9.16	Vol343.22K
Open9.32	D1 Closing9.23	Amplitude3.32%
Mkt Cap276.59M	Tradable Cap194.57M	Total Shares29.71M
T/O3.20M	T/O Rate1.64%	Tradable Shares20.90M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"QTTB","market":"US","secType":"STK","nameCN":"Q32 Bio Inc.","latestPrice":9.31,"timestamp":1790699987511,"preClose":9.23,"halted":0,"volume":343220,"delay":0,"changeRate":0.008667388949079096,"floatShares":20898500,"shares":29708800,"eps":3.0012,"marketStatus":"Trading","change":0.08,"latestTime":"09-29 12:40:08 EDT","open":9.32,"high":9.47,"low":9.164,"amount":3199040.3574,"amplitude":0.033153,"askPrice":9.35,"askSize":100,"bidPrice":9.3,"bidSize":124,"shortable":3,"etf":0,"ttmEps":3.0012,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1790712000000},"marketStatusCode":2,"adr":0,"listingDate":1522209600000,"exchange":"NASDAQ","adjPreClose":9.23,"preHourTrading":{"tag":"盘前","latestPrice":9.32,"preClose":9.23,"latestTime":"09:29 EDT","volume":6832,"amount":66592.556128,"timestamp":1790688599999,"change":0.09,"changeRate":0.009751,"amplitude":0.106176},"postHourTrading":{"tag":"盘后","latestPrice":9.7517,"preClose":9.23,"latestTime":"19:58 EDT","volume":41267,"amount":390631.3716,"timestamp":1790639929625,"change":0.5217,"changeRate":0.056522,"amplitude":0.071506},"volumeRatio":0.919247,"impliedVol":1.2285,"impliedVolPercentile":0.6324},"requestUrl":"/m/hq/s/QTTB","defaultTab":"news","newsList":[{"id":"2671169572","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2671169572","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671169572?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:12","pubTimestamp":1790680360,"startTime":"0","endTime":"0","summary":"Summit Therapeutics  shares were up more than 23% pre-bell Tuesday after AstraZeneca  agreed to invest $2 billion in convertible preferred shares in Summit, along with a nonbinding clinical collaboration focused on ivonescimab and sonesitatug vedotin.Navitas Semiconductor  stock was 12% higher after the company said late Monday it was awarded the Accelerated, Large-Area, 10 kV SiC IGBT program to develop next-generation 10-kilovolt silicon carbide power semiconductor technology.Q32 Bio  shares were up 9% after Jefferies initiated the company's coverage at buy with a $29 price target.Deep Fission  stock was 8.7% higher, partially reversing the 13% loss at Monday's close.Armada Acquisition Corp. II  shares were up over 8% after a marginal retreat at the prior close.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0432979614.USD","BK4585","NVTX","LU2237443622.USD","BK4007","QTTB","BK4568","BK4105","LU0109394709.USD","LU2237443895.HKD","AZN","LU0310800379.SGD","IE00B3T34201.USD","LU2417539215.USD","LU0128525929.USD","AZNH","LU2488822045.USD","LU0029864427.USD","NVTS","LU0708994859.HKD","LU1829250122.USD","LU2237443978.SGD","FISN","LU1267930573.SGD","LU0058720904.USD","LU0320765992.SGD","LU0289739699.SGD","LU2236285917.USD","LU2089984988.USD","BK4588","LU2237443465.HKD","LU2456880835.USD","LU0889565916.HKD","LU2462157665.USD","BK4139","NVTC","SMMT","LU2237443549.SGD","LU2468319806.SGD","XRPN","BK4141","LU2237443382.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671215498","title":"Q32 Bio Inc. : Clear Street Initiates Coverage with Buy Rating; Price Target $38","url":"https://stock-news.laohu8.com/highlight/detail?id=2671215498","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671215498?lang=en_us&edition=fundamental","pubTime":"2026-09-29 18:56","pubTimestamp":1790679407,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nFWN45L0XU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QTTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670395532","title":"Jefferies Initiates Q32 Bio at Buy With $29 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2670395532","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670395532?lang=en_us&edition=fundamental","pubTime":"2026-09-28 18:43","pubTimestamp":1790592217,"startTime":"0","endTime":"0","summary":"Q32 Bio (QTTB) has an average rating of buy and mean price target of $42.25, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and r","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["QTTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670239307","title":"Q32 Bio initiated with a Buy at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2670239307","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670239307?lang=en_us&edition=fundamental","pubTime":"2026-09-28 18:31","pubTimestamp":1790591464,"startTime":"0","endTime":"0","summary":"Jefferies analyst Maury Raycroft initiated coverage of Q32 Bio (QTTB) with a Buy rating and $29 price target Q32 “remains mispriced” compared to it...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/q32-bio-initiated-with-a-buy-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/q32-bio-initiated-with-a-buy-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QTTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669625001","title":"Q32 Bio to Present 36-Week Phase 2a Signal-AA Trial Data for Bempikibart in Alopecia Areata at EADV 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2669625001","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669625001?lang=en_us&edition=fundamental","pubTime":"2026-09-22 00:17","pubTimestamp":1790007432,"startTime":"0","endTime":"0","summary":"Q32 Bio to present 36-week Phase 2a SIGNAL-AA trial data for bempikibart in alopecia areata at EADV 2026Q32 Bio flagged new 36-week results from its Phase 2a SIGNAL-AA Part B trial of bempikibart in s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nNDL20g7Kh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669166661","title":"Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the Signal-Aa Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2669166661","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669166661?lang=en_us&edition=fundamental","pubTime":"2026-09-21 21:15","pubTimestamp":1789996531,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nTUA2QTFBN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QTTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667865044","title":"Q32 Bio Names José Trevejo Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2667865044","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667865044?lang=en_us&edition=fundamental","pubTime":"2026-09-14 18:59","pubTimestamp":1789383556,"startTime":"0","endTime":"0","summary":"Q32 Bio names José Trevejo chief medical officerQ32 Bio named José Trevejo as chief medical officer.Trevejo was chief medical officer and head of clinical pipeline strategy at Enveda Therapeutics.Earl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nNDLbs27vy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RCKT","IVVD","QTTB","TARS","BK4539","SRNE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667365041","title":"Q32 Bio Appoints JosÉ Trevejo, M.d., Ph.d., as Chief Medical Officer and Ellie Hershberger, Pharm.d., as Chief Development Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2667365041","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667365041?lang=en_us&edition=fundamental","pubTime":"2026-09-14 18:59","pubTimestamp":1789383540,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUA6SYXLV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QTTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666193374","title":"Q32 Bio on Track for Longest Losing Streak Since November 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2666193374","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666193374?lang=en_us&edition=fundamental","pubTime":"2026-09-09 02:03","pubTimestamp":1788890580,"startTime":"0","endTime":"0","summary":"Q32 Bio Inc  is currently at $11.92, down $0.06 or 0.54%--Would be lowest close since July 10, 2026, when it closed at $11.21--On pace for largest percent decrease since Sept. 4, 2026, when it fell 6.33%--Currently down 10 consecutive days; down 27.11% over this period--Longest losing streak since Nov. 22, 2024, when it fell for 12 straight trading days--Worst 10-day stretch since the 10 days ending July 27, 2026, when it fell 28.86%--Down 19.8% month-to-date--Up 259.19% year-to-date--Down 97.82% from its all-time closing high of $546.12 on April 5, 2019--Up 569.94% from 52 weeks ago , when it closed at $1.78--Down 44.22% from its 52-week closing high of $21.38 on July 13, 2026--Up 585.34% from its 52-week closing low of $1.74 on Sept. 18, 2025--Traded as low as $11.57--Down 3.54% at today's intraday lowAll data as of 1:57:59 PM ETSource: Dow Jones Market Data, FactSet","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QTTB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664498853","title":"Q32 Bio to Present at Wells Fargo Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664498853","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664498853?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:59","pubTimestamp":1788260359,"startTime":"0","endTime":"0","summary":"Q32 Bio to Present at Wells Fargo Healthcare ConferenceQ32 Bio management will attend investor conferences on Sept. 8, Sept. 9, Sept. 15, 2026.Fireside chats set for 3:45 p.m. ET in Boston, 3:55 p.m. ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL4fX22D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661427839","title":"Q32 Bio Initiated at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2661427839","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661427839?lang=en_us&edition=fundamental","pubTime":"2026-08-24 18:28","pubTimestamp":1787567280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/QTTB/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661222536","title":"Q32 Bio initiated with an Overweight at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2661222536","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661222536?lang=en_us&edition=fundamental","pubTime":"2026-08-24 17:10","pubTimestamp":1787562606,"startTime":"0","endTime":"0","summary":"Morgan Stanley initiated coverage of Q32 Bio (QTTB) with an Overweight rating and $34 price target Q32 is a clinical-stage immunology company devel...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/q32-bio-initiated-with-an-overweight-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/q32-bio-initiated-with-an-overweight-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","QTTB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657687203","title":"Q32 Bio Inc. : Wells Fargo Cuts Target Price to $59 from $66","url":"https://stock-news.laohu8.com/highlight/detail?id=2657687203","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657687203?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:44","pubTimestamp":1786013069,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN44317I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QTTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657524750","title":"Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Q32 Bio (QTTB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657524750","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657524750?lang=en_us&edition=fundamental","pubTime":"2026-08-06 02:30","pubTimestamp":1785954614,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vertex Pharmaceuticals (VRTX) and Q32 Bio (QTTB) wit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vertex-pharmaceuticals-vrtx-and-q32-bio-qttb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vertex-pharmaceuticals-vrtx-and-q32-bio-qttb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B19Z3581.USD","LU1585245621.USD","IE00B2B36J28.USD","LU0889565916.HKD","LU2417539215.USD","VERX","LU0289739699.SGD","SG9999001176.SGD","LABU","BBH","BK4588","LU0109394709.USD","LU2468319806.SGD","LU0029874061.USD","VRTX","LU0079474960.USD","XBI","GNMX","XLV","IBB","LU2362541513.USD","LU0256863811.USD","BIB","SG9999001176.USD","LU0823416689.USD","IE00B19Z9P08.USD","TBXU","IBBQ","LU0061475181.USD","LU1815336091.USD","LU2462157665.USD","IDNA","LU0417517546.SGD","QTTB","BK4581","IE00B19Z9Z06.USD","LU1093756168.USD","IE00BJT1NW94.SGD","LU1093756325.SGD","SGXZ57979304.SGD","HCSG","LU1430594728.SGD","LU2089984988.USD","PBE","BK4023","LU2362541273.HKD","LU1069344957.HKD","IE00B19Z3B42.SGD","BK4532","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657054437","title":"Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657054437","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657054437?lang=en_us&edition=fundamental","pubTime":"2026-08-05 20:09","pubTimestamp":1785931754,"startTime":"0","endTime":"0","summary":"BRIEF-Q32 Bio Reports Second Quarter 2026 Financial Results And Provides Corporate UpdateAug 5 (Reuters)-Q32 Bio Inc.QTTB.O:Q32 BIO REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATESource text:ID:nPn4s7hczaFurther company coverage:QTTB.O","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nTUACC3XNS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657680541","title":"Q32 Bio Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657680541","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657680541?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:51","pubTimestamp":1785930687,"startTime":"0","endTime":"0","summary":"Q32 Bio Inc. reports results for the quarter ended June 30 - Earnings SummaryQ32 Bio Inc.QTTB.OQreported a quarterly adjusted loss of 44 cents per share for the quarter ended June 30, higher than the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL8N4421MX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657549852","title":"Q32 Bio Q2 EPS $(0.44) Beats $(0.54) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657549852","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657549852?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:21","pubTimestamp":1785928861,"startTime":"0","endTime":"0","summary":"Q32 Bio (NASDAQ:QTTB) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.54) by 18.52 percent. This is a 43.59 percent increase over losses of $(0.78) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60943804/q32-bio-q2-eps-0-44-beats-0-54-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657907545","title":"Q32 Bio Q2 FY26 Net Loss Narrows to $8.95 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657907545","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657907545?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:59","pubTimestamp":1785927579,"startTime":"0","endTime":"0","summary":"Q32 Bio Q2 FY26 net loss narrows to $8.95 millionQ32 Bio posted a net loss of USD 8.95 million, narrowing from USD 9.49 million a year earlier; loss per share improved to USD 0.44.R&D expense fell 17.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL2wzvmS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656925376","title":"Akebia Initiates Phase 2 Basket Trial of Complement Inhibitor Ebribafusp in Rare Kidney Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2656925376","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656925376?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:02","pubTimestamp":1785758533,"startTime":"0","endTime":"0","summary":"Akebia initiates Phase 2 basket trial of complement inhibitor ebribafusp in rare kidney diseasesAkebia Therapeutics launched a Phase 2 basket trial of ebribafusp for rare complement-mediated kidney di","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL3chdgM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2210149790.SGD","LU0314104364.USD","NDAQ","SG9999014021.USD","BK4112","AKBA","BK4585","BK4588","SG9999014039.USD","QTTB","BK4139","BCDF","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","LU2095319765.USD","SG9999014013.SGD","IE00BKPKM429.USD","LU2210150020.SGD","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","IE00BGHQF748.EUR","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655369038","title":"Q32 Bio Inc Expected to Post a Loss of 54 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2655369038","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655369038?lang=en_us&edition=fundamental","pubTime":"2026-07-31 21:05","pubTimestamp":1785503104,"startTime":"0","endTime":"0","summary":"Q32 Bio Inc <QTTB.OQ> expected to post a loss of54cents a share - Earnings PreviewQ32 Bio IncQTTB.OQQTTB.Ois expected to  show no change in quarterly revenue when it reports  results on August 4 (esti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nL8N43X1XC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QTTB"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.q32bio.com","stockEarnings":[{"period":"1week","weight":-0.1184},{"period":"1month","weight":-0.3859},{"period":"3month","weight":-0.2755},{"period":"6month","weight":0.5106},{"period":"1year","weight":3.8836},{"period":"ytd","weight":1.7801}],"compareEarnings":[{"period":"1week","weight":-0.0102},{"period":"1month","weight":-0.0049},{"period":"3month","weight":0.0252},{"period":"6month","weight":0.1684},{"period":"1year","weight":0.1568},{"period":"ytd","weight":0.1227}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.019777},{"month":2,"riseRate":0.5,"avgChangeRate":0.070572},{"month":3,"riseRate":0.25,"avgChangeRate":-0.062438},{"month":4,"riseRate":0.222222,"avgChangeRate":-0.082275},{"month":5,"riseRate":0.555556,"avgChangeRate":0.111875},{"month":6,"riseRate":0.555556,"avgChangeRate":0.01181},{"month":7,"riseRate":0.555556,"avgChangeRate":0.224049},{"month":8,"riseRate":0.444444,"avgChangeRate":-0.026666},{"month":9,"riseRate":0.555556,"avgChangeRate":-0.011204},{"month":10,"riseRate":0.25,"avgChangeRate":-0.055418},{"month":11,"riseRate":0.375,"avgChangeRate":-0.113432},{"month":12,"riseRate":0.625,"avgChangeRate":-0.026783}],"exchange":"NASDAQ","name":"Q32 Bio Inc.","nameEN":"Q32 Bio Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Q32 Bio Inc.(QTTB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Q32 Bio Inc.(QTTB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Q32 Bio Inc.,QTTB,Q32 Bio Inc.股票,Q32 Bio Inc.股票老虎,Q32 Bio Inc.股票老虎国际,Q32 Bio Inc.行情,Q32 Bio Inc.股票行情,Q32 Bio Inc.股价,Q32 Bio Inc.股市,Q32 Bio Inc.股票价格,Q32 Bio Inc.股票交易,Q32 Bio Inc.股票购买,Q32 Bio Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Q32 Bio Inc.(QTTB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Q32 Bio Inc.(QTTB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction